By Mike Ward
Editor, Europe

OXFORD - Following last week's FDA panel meeting, Chiroscience Group plc (LSE:CRO) intends to demonstrate that its long acting local anesthetic Chirocaine levobupivacaine is safer than existing products. Such a safety claim is considered essential to CRO's desire to capture a significant market share of the local anesthetic market, including capturing ground from Astra AB's competing products, bupivacaine and ropivacaine.